Avalo Therapeutics Files Q2 2024 10-Q
Ticker: AVTX · Form: 10-Q · Filed: Aug 12, 2024 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | 10-Q |
| Filed Date | Aug 12, 2024 |
| Risk Level | medium |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials
Related Tickers: AVTX
TL;DR
Avalo Therapeutics (AVTX) dropped its Q2 10-Q. Check financials.
AI Summary
Avalo Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Cerecor Inc., reported financial results and operational updates. Key financial data and disclosures related to its pharmaceutical preparations business are included in this filing.
Why It Matters
This filing provides investors and stakeholders with the latest financial health and operational status of Avalo Therapeutics, Inc. as of mid-2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Avalo Therapeutics is subject to inherent risks in drug development, regulatory approvals, and market competition.
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Filer of the 10-Q
- Cerecor Inc. (company) — Former name of Avalo Therapeutics, Inc.
- 20240630 (date) — End of the reporting period
- 20240812 (date) — Filing date of the 10-Q
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is June 30, 2024.
What was Avalo Therapeutics, Inc. formerly known as?
Avalo Therapeutics, Inc. was formerly known as Cerecor Inc.
What is the Standard Industrial Classification code for Avalo Therapeutics?
The Standard Industrial Classification code for Avalo Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
On what date was this 10-Q filed?
This 10-Q was filed on August 12, 2024.
In which state was Avalo Therapeutics, Inc. incorporated?
Avalo Therapeutics, Inc. was incorporated in Delaware (DE).
Filing Stats: 4,796 words · 19 min read · ~16 pages · Grade level 16.6 · Accepted 2024-08-12 07:03:17
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value AVTX Nasdaq Capital Market
Filing Documents
- avtx-20240630.htm (10-Q) — 1144KB
- ex-3112q2024.htm (EX-31.1) — 10KB
- ex-3122q2024.htm (EX-31.2) — 10KB
- ex-3212q2024.htm (EX-32.2) — 11KB
- avtx-20240630_g1.jpg (GRAPHIC) — 188KB
- 0001628280-24-036591.txt ( ) — 7217KB
- avtx-20240630.xsd (EX-101.SCH) — 57KB
- avtx-20240630_cal.xml (EX-101.CAL) — 72KB
- avtx-20240630_def.xml (EX-101.DEF) — 338KB
- avtx-20240630_lab.xml (EX-101.LAB) — 601KB
- avtx-20240630_pre.xml (EX-101.PRE) — 461KB
- avtx-20240630_htm.xml (XML) — 849KB
Financial Statements
Financial Statements a) Condensed Consolidated Balance Sheets as of June 3 0 , 2024 (Unaudited) and December 31, 2023 3 b) Condensed Consolidated Statements of Operations and Comprehensive Income ( Los s ) (Unaudited) for the Three and Six Months Ended June 3 0 , 2024 and 2023 5 c) Condensed Consolidated Statements of Preferred Stock and Changes in Stockholders' Deficit (Unaudited) for the Three and Six Months Ended June 3 0 , 2024 and 2023 6 d) Condensed Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 3 0 , 2024 and 2023 8 e) Notes to Unaudited Condensed Consolidated Financial Statements 10 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 35 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 46 Item 4.
Controls and Procedures
Controls and Procedures 46 PART II. OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 47 Item 1A.
Risk Factors
Risk Factors 47 Item 6. Exhibits 51
SIGNATURES
SIGNATURES 52 2 Table of Contents
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements. AVALO THERAPEUTICS, INC. and SUBSIDIARIES Condensed Consolidated Balance Sheets (In thousands, except share and per share data) 3 Table of Contents June 30, 2024 December 31, 2023 (unaudited) Assets Current assets: Cash and cash equivalents $ 93,426 $ 7,415 Other receivables 33 136 Prepaid expenses and other current assets 2,435 843 Restricted cash, current portion — 1 Total current assets 95,894 8,395 Property and equipment, net 1,780 1,965 Goodwill 10,502 10,502 Restricted cash, net of current portion 131 131 Total assets $ 108,307 $ 20,993 Liabilities, mezzanine equity and stockholders' (deficit) equity Current liabilities: Accounts payable $ 654 $ 446 Accrued expenses and other current liabilities 7,888 4,172 Warrant liability 82,855 — Contingent consideration 5,000 — Total current liabilities 96,397 4,618 Royalty obligation 2,000 2,000 Deferred tax liability, net 168 155 Derivative liability 10,710 5,550 Other long-term liabilities 1,183 1,366 Total liabilities 110,458 13,689 Mezzanine equity: Series C Preferred Stock—$ 0.001 par value; 34,326 and 0 shares of Series C Preferred Stock authorized at June 30, 2024 and December 31, 2023, respectively; 22,358 and 0 shares of Series C Preferred Stock issued and outstanding at June 30, 2024 and December 31, 2023, respectively 11,457 — Series D Preferred Stock—$ 0.001 par value; 1 and 0 shares of Series D Preferred Stock authorized at June 30, 2024 and December 31, 2023, respectively; 1 and 0 shares of Series D Preferred Stock issued and outstanding at June 30, 2024 and December 31, 2023, respectively — — Series E Preferred Stock—$ 0.001 par value; 1 and 0 shares of Series E Preferred Stock authorized at June 30, 2024 and December 31, 2023, respectively; 1 and 0 shares of Series E Preferred Stock issued and outstanding at June 30, 2024 and December 31, 2023, respectively — — Stockholders' (deficit) equity: Common stock—$ 0.001 par value; 200,00